Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for JIA-Associated Uveitis
NCT01603355Phase 2Terminated
- Start
- Nov 2013
- Primary completion
- Feb 2016
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in juvenile idiopathic arthritis-associated uveitis (JIAU). Started Nov 2013; status: terminated.
02
Drugs
tocilizumab
03
Conditions
juvenile idiopathic arthritis-associated uveitis (JIAU)
Beyond the preview
Go deeper on NCT01603355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01603355.